Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCC and TXA Effects on Bleeding in Rivaroxaban-Treated Healthy Subjects
NCT02561923Phase 1Completed
- Sponsor
- Janssen Scientific Affairs
- Start
- Aug 2015
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of coagulation factor X human and tranexamic acid in hemorrhage (4 arms), sponsored by Janssen Scientific Affairs. Primary endpoints: Change From Baseline in Blood Volume in Part 1, Change From Baseline in Bleeding Duration in Part 1 and 7 more. Started Aug 2015; status: completed.
02
Drugs
coagulation factor X humantranexamic acid
03
Conditions
hemorrhage
Beyond the preview
Go deeper on NCT02561923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561923.